BD Completes Clinical Trial for BD Libertas Wearable Injector

 BD (Becton, Dickinson and Company), a global medical technology company, has completed a 50-subject human clinical trial with the BD Libertas Wearable Injector.
 
The injector is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.
 
The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced sometime in 2020.
 
The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.
 
Commenting on the study, Peter Nolan, worldwide president of BD Pharmaceutical Systems, said, “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”
 
In February, BD announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low- and middle-income countries around the world tackle antimicrobial resistance (AMR).
 
Through this agreement, BD will provide diagnostic equipment and informatics solutions that help aid in the diagnosis of infections and guide physicians to provide appropriate antimicrobial prescribing and use.
 
Specifically, BD will equip more than 70 labs with solutions that include the BD BACTEC FX40 Blood Culture System designed for the rapid detection of bacteria and fungi in clinical specimens; blood and blood products; the BD Phoenix M50 Automated Microbiology System for the rapid identification (ID) and Antimicrobial Susceptibility Testing (AST) of clinically significant bacteria; and the BD Bruker MALDI Biotyper System for the rapid identification (ID) of microorganisms. For microbiology data management and informatics solutions, BD will be providing the BD EpiCenter Microbiology Data Management System and the BD Synapsys Microbiology Informatics Solution.
 
The program is funded by the U.K. Department of Health and Social Care and delivered by Mott MacDonald, the Fleming Fund Grant Management Agent for Fellowships, Regional and Country Grants.